4//SEC Filing
Lappe Mark 4
Accession 0000950142-24-001493
CIK 0002007919other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:10 PM ET
Size
12.2 KB
Accession
0000950142-24-001493
Insider Transaction Report
Form 4
Lappe Mark
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2024-05-29+14,865→ 14,865 total(indirect: By IRA) - Award
Common Stock
2024-05-29+621,548→ 621,548 total(indirect: By Trust) - Award
Common Stock
2024-05-29+125,000→ 125,000 total(indirect: By Trust) - Award
Stock Option (right to buy)
2024-05-30+300,000→ 300,000 totalExercise: $15.86Exp: 2034-05-30→ Common Stock (300,000 underlying)
Footnotes (5)
- [F1]The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9.
- [F2]These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
- [F3]These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
- [F4]This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi.
- [F5]Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Documents
Issuer
Inhibrx Biosciences, Inc.
CIK 0002007919
Entity typeother
Related Parties
1- filerCIK 0001366074
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:10 PM ET
- Size
- 12.2 KB